Trial NCT01149356

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2010-02181
Secondary IDs: 8539 CDR0000675612 MCC-8539 N01CM00100 NCI-2010-02181 P30CA076292

Last trial update was posted on 2015-05-25

MeSH Interventions

2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide Exemestane Gamma Secretase Inhibitors and Modulators Goserelin

MeSH Conditions

Breast Neoplasms Breast Neoplasms, Male Carcinoma

Other Conditions

Estrogen Receptor Positive HER2/Neu Negative Male Breast Carcinoma Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer

Stopping Reasons

Manufacturer discontinued drug development.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID